Asset / Drug

TR115

Drug and asset intelligence for TR115 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

EZH2 Inhibitor

ClinicalJune 15, 2026

A Phase III trial is underway to evaluate TR115, an EZH2 inhibitor, against standard treatments in relapsed/refractory peripheral T/NK-cell lymphoma.

No catalysts indexed for this entity yet.

Topline Data

Monitor progression-free survival and overall survival results, as well as enrollment updates from the trial sites in China.

June 15, 2026 · N/A

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.